Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients (TROFI)
Primary Purpose
Coronary Artery Disease, Myocardial Infarction, STEMI
Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
primary PCI with thrombectomy
primary PCI without thrombectomy
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring thrombus aspiration, Drug-Eluting Stent, optical frequency domain imaging (OFDI)
Eligibility Criteria
Inclusion Criteria:
- Patient is at least 18 years of age.
- Patients with a ST-elevation Myocardial Infarction documented in an ambulance or in a Cathlab with ≥2 mm ST segment elevation in at least two contiguous leads, presenting in the Cathlab <12 hours after the onset of symptoms lasting ≥20 min and having an angiographical visible stenosis (>30%) or TIMI≤ II in de-novo, native, previously unstented vessel.
- The single vessel coronary artery disease.
- Signed Informed Consent.
- The patient understands and accepts clinical follow-up and OFDI controls.
- Patients residence is in the area covered by hospital. Angiographic
- Vessel size should match available Nobori stent sizes (<4.0 mm, and >2.0 mm by visual assessment).
Additional Inclusion criteria (applicable only for France)
- Patients residence is in the area covered by hospital.
- Patient is affiliated to social security or equivalent system.
Exclusion Criteria:
- Pregnancy and women of child bearing potential (less than 50 years of age).
- Known intolerance to aspirin, clopidogrel, heparin, stainless steel, Biolimus A9, contrast material.
- Diameter Stenosis <30% in the target lesion.
- The multi-vessel coronary artery disease (DS>50%).
- Unprotected left main disease with a diameter stenosis of >30% by visual assessment.
- Distal vessel occlusion.
- Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in sub-optimal imaging or excessive risk of complication from placement of an OFDI catheter.
- Fibrinolysis prior to PCI.
- Known thrombocytopaenia (PLT< 100,000/mm3).
- Contraindication to PCI, stenting, ASA, clopidogrel.
- Active bleeding or coagulopathy or patients at chronic anticoagulation therapy.
- Cardiogenic Shock.
- Significant comorbidities precluding clinical follow-up (as judged by investigators).
- Major planned surgery that requires discontinuation of dual antiplatelet therapy.
- Proximal RCA stenosis (>30%) if the infarct-related artery is mid-RCA or distal-RCA.
- People under judicial protection.
- A patient who has congenital heart disease, severe cardiac valve disorder and/or myocardial disease (excluding status post MI).
- Patient participating in other clinical research study.
Sites / Locations
- Aarhus University Hospital Skejby
- Clinique Pasteur
- Universität Leipzig - Herzzentrum
- Erasmus Medical Center
- Maastad Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
primary PCI with thrombectomy
primary PCI without thrombectomy
Arm Description
thrombectomy before implantation of drug eluting stent
implantation of a drug eluting stent without thrombectomy
Outcomes
Primary Outcome Measures
minimal flow area assessed by OFDI
Flow area is defined as: (Stent area + incomplete stent apposition area) - (intraluminal defect area attached to the wall + intraluminal defect area free from the wall)
Secondary Outcome Measures
normalised minimal flow area
defined as the ratio of minimal flow divided by stent area at the site of the minimal flow area
mean flow area/volume
intraluminal defect area/volume
mean stent area/volume
percent of malapposed struts
incomplete stent apposition (ISA) area/volume
percent of struts with coverage
healing index
tissues prolapse area/volume
procedure success
attainment of <30% residual stenosis of the target lesion and no in-hospital target vessel failure
target vessel failure
defined as cardiac death, reinfarction in the territory of infarction related vessel (Q wave and non-Q wave), or clinically driven target vessel revascularization - and its individual components
all-cause mortality
cardiac death, non-cardiovascular death, vascular death
any myocardial (re)infarction
target vessel revascularization
stent thrombosis according to ARC definition
other serious adverse events (SAEs)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01271361
Brief Title
Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients
Acronym
TROFI
Official Title
Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients: an Optical Frequency Domain Imaging (OFDI) Study
Study Type
Interventional
2. Study Status
Record Verification Date
December 2012
Overall Recruitment Status
Completed
Study Start Date
November 2010 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Terumo Europe N.V.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study it to evaluate whether primary percutaneous coronary intervention (primary PCI) with a new thrombectomy device as compared to primary PCI without thrombectomy increases minimal flow area after stenting for treatment of patients presenting with ST-segment elevation myocardial infarction (STEMI) as assessed by OFDI.
Detailed Description
Primary percutaneous coronary intervention has been well established as the treatment of choice for the majority of patients presenting with acute ST elevation myocardial infarction (STEMI). However primary PCI alone is unable to remove intracoronary thrombus and this often results in distal embolisation, no reflow which in turn leads to impaired myocardial perfusion. This can result in left ventricular dysfunction and subsequently increased mortality.
The use of thrombectomy devices during percutaneous coronary intervention in the setting of acute ST elevation myocardial infarction has been recently shown to improve epicardial, myocardial perfusion, angiographical TIMI flow, blush score, or result in less embolisation. Moreover thrombus aspiration or rheolysis has been shown to decrease cardiac death and repeat myocardial infarction.
It is estimated that late stent malapposition is more common after stenting in the course of primary PCI as compared with elective PCI, and may predispose to stent thrombosis. Late malapposition may be related to underdeployment of stents at the time of primary PCI, and this may be due in part to thrombus behind the stent, which subsequently resolves and leads to stent malapposition. Removal of thrombus before stenting potentially could lead to better stent expansion and less late malapposition.
On the other hand, the impact of thrombus on acute and chronic luminal dimension is still unclear in a setting of primary PCI. After stenting, such thrombus either I) protrude into the lumen through the mesh of metallic stent struts or II) is crushed between the vessel wall and stent. Theoretically, the protruded thrombus can hinder the intra-luminal flow immediately after stenting, while the resorption of crushed thrombus against vessel wall might result at long term in stent malaposition.
Due to the limited ability of the conventional angiography and the intravascular ultrasound (IVUS) to detect thrombus, these aspects have not been investigated.
Optical coherence tomography has recently been shown to be feasible and to provide valuable information in the setting of acute myocardial infarction. This imaging modality has been shown to be even more sensitive to detect intraluminal mass (i.e. thrombus) and offers unique possibilities of analysis of coronary intervention in acute myocardial infarction.
TERUMO OFDI is a novel optical imaging device that uses a scanning laser as light source which centre wavelength is around 1.3 μm with sweeping range over 100 nm. The echo-time delay and the amplitude of light reflected from the tissue microstructure at different depths are determined by processing the interference between the tissue sample and a fixed reference mirror.
Compared to the conventional OCT imaging devices, OFDI has a higher temporal frame rate (160 frames/sec), with a faster pullback speed of maximally up to 40 mm/s. The safety and performance of the device has been investigated in the First-in-man study enrolling 19 patients where both IVUS and OFDI were performed. In the study, OFDI was associated with no device-related adverse events, and with a good correlation with IVUS measurement.
We hypothesize that TERUMO Eliminate® thrombectomy device will reduce the thrombus burden in STEMI patients and this will result in less intraluminal material and larger flow area, measured with OFDI. This will be clinically translated in a better restoration of blood flow and reduce further damage of the myocardium.
In addition, a reduction of thrombus burden would eventually result in less stent malaposition at 6 months. Given the benefits of reducing thrombus burden in STEMI as described above, the study may have important implications on the prove of the effectiveness of the thrombectomy device and the use of this imaging modality to assess its efficacy. To best assess benefits of thrombus removal, a randomized controlled study was considered the most appropriate method.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Myocardial Infarction, STEMI
Keywords
thrombus aspiration, Drug-Eluting Stent, optical frequency domain imaging (OFDI)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
140 (Actual)
8. Arms, Groups, and Interventions
Arm Title
primary PCI with thrombectomy
Arm Type
Experimental
Arm Description
thrombectomy before implantation of drug eluting stent
Arm Title
primary PCI without thrombectomy
Arm Type
Active Comparator
Arm Description
implantation of a drug eluting stent without thrombectomy
Intervention Type
Procedure
Intervention Name(s)
primary PCI with thrombectomy
Other Intervention Name(s)
Eliminate thrombectomy device, Nobori Biolimus A9 drug-eluting stent
Intervention Description
thrombectomy is performed before implantation of a drug eluting stent
Intervention Type
Procedure
Intervention Name(s)
primary PCI without thrombectomy
Other Intervention Name(s)
Nobori Biolimus A9 drug-eluting stent
Intervention Description
no thrombectomy is performed before the implantation of a drug eluting stent
Primary Outcome Measure Information:
Title
minimal flow area assessed by OFDI
Description
Flow area is defined as: (Stent area + incomplete stent apposition area) - (intraluminal defect area attached to the wall + intraluminal defect area free from the wall)
Time Frame
at baseline procedure (post-stenting)
Secondary Outcome Measure Information:
Title
normalised minimal flow area
Description
defined as the ratio of minimal flow divided by stent area at the site of the minimal flow area
Time Frame
at baseline procedure (post stenting)
Title
mean flow area/volume
Time Frame
at baseline procedure (post stenting) and at 6 months
Title
intraluminal defect area/volume
Time Frame
at baseline procedure (post stenting) and at 6 months
Title
mean stent area/volume
Time Frame
at baseline procedure (post stenting) and at 6 months
Title
percent of malapposed struts
Time Frame
at baseline procedure (post stenting) and at 6 months
Title
incomplete stent apposition (ISA) area/volume
Time Frame
at baseline procedure (post stenting) and at 6 months
Title
percent of struts with coverage
Time Frame
at 6 months
Title
healing index
Time Frame
at 6 months
Title
tissues prolapse area/volume
Time Frame
at 6 months
Title
procedure success
Description
attainment of <30% residual stenosis of the target lesion and no in-hospital target vessel failure
Time Frame
at baseline procedure
Title
target vessel failure
Description
defined as cardiac death, reinfarction in the territory of infarction related vessel (Q wave and non-Q wave), or clinically driven target vessel revascularization - and its individual components
Time Frame
at discharge, 1 month, 6 months and 12 months
Title
all-cause mortality
Time Frame
at discharge, 1 month, 6 months and 12 months
Title
cardiac death, non-cardiovascular death, vascular death
Time Frame
at discharge, 1 month, 6 months and 12 months
Title
any myocardial (re)infarction
Time Frame
at discharge, 1 month, 6 months and 12 months
Title
target vessel revascularization
Time Frame
at discharge, 1 month, 6 months and 12 months
Title
stent thrombosis according to ARC definition
Time Frame
at discharge, 1 month, 6 months and 12 months
Title
other serious adverse events (SAEs)
Time Frame
at discharge, 1 month, 6 months and 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is at least 18 years of age.
Patients with a ST-elevation Myocardial Infarction documented in an ambulance or in a Cathlab with ≥2 mm ST segment elevation in at least two contiguous leads, presenting in the Cathlab <12 hours after the onset of symptoms lasting ≥20 min and having an angiographical visible stenosis (>30%) or TIMI≤ II in de-novo, native, previously unstented vessel.
The single vessel coronary artery disease.
Signed Informed Consent.
The patient understands and accepts clinical follow-up and OFDI controls.
Patients residence is in the area covered by hospital. Angiographic
Vessel size should match available Nobori stent sizes (<4.0 mm, and >2.0 mm by visual assessment).
Additional Inclusion criteria (applicable only for France)
Patients residence is in the area covered by hospital.
Patient is affiliated to social security or equivalent system.
Exclusion Criteria:
Pregnancy and women of child bearing potential (less than 50 years of age).
Known intolerance to aspirin, clopidogrel, heparin, stainless steel, Biolimus A9, contrast material.
Diameter Stenosis <30% in the target lesion.
The multi-vessel coronary artery disease (DS>50%).
Unprotected left main disease with a diameter stenosis of >30% by visual assessment.
Distal vessel occlusion.
Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in sub-optimal imaging or excessive risk of complication from placement of an OFDI catheter.
Fibrinolysis prior to PCI.
Known thrombocytopaenia (PLT< 100,000/mm3).
Contraindication to PCI, stenting, ASA, clopidogrel.
Active bleeding or coagulopathy or patients at chronic anticoagulation therapy.
Cardiogenic Shock.
Significant comorbidities precluding clinical follow-up (as judged by investigators).
Major planned surgery that requires discontinuation of dual antiplatelet therapy.
Proximal RCA stenosis (>30%) if the infarct-related artery is mid-RCA or distal-RCA.
People under judicial protection.
A patient who has congenital heart disease, severe cardiac valve disorder and/or myocardial disease (excluding status post MI).
Patient participating in other clinical research study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick W Serruys, MD
Organizational Affiliation
Erasmus Medical Center, Rotterdam, Netherlands
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aarhus University Hospital Skejby
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Facility Name
Clinique Pasteur
City
Toulouse
ZIP/Postal Code
31076
Country
France
Facility Name
Universität Leipzig - Herzzentrum
City
Leipzig
ZIP/Postal Code
04289
Country
Germany
Facility Name
Erasmus Medical Center
City
Rotterdam
ZIP/Postal Code
3000CA
Country
Netherlands
Facility Name
Maastad Hospital
City
Rotterdam
ZIP/Postal Code
3015EA
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
19004841
Citation
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12. No abstract available.
Results Reference
background
PubMed Identifier
10547403
Citation
Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van 't Hof AW, Suryapranata H. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999 Nov 4;341(19):1413-9. doi: 10.1056/NEJM199911043411901.
Results Reference
background
PubMed Identifier
10607811
Citation
Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999 Dec 23;341(26):1949-56. doi: 10.1056/NEJM199912233412601.
Results Reference
background
PubMed Identifier
17692740
Citation
Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83. doi: 10.1016/j.jacc.2007.04.059. Epub 2007 Jul 30.
Results Reference
background
PubMed Identifier
16883024
Citation
Sianos G, Papafaklis MI, Vaina S, Daemen J, van Mieghem CA, Van Domburg RT, Michalis LK, de Jaegere P, Serruys PW. Rheolytic thrombectomy in patients with ST-elevation myocardial infarction and large thrombus burden: the Thoraxcenter experience. J Invasive Cardiol. 2006 Jul;18 Suppl C:3C-7C.
Results Reference
background
PubMed Identifier
19850252
Citation
Haeck JD, Koch KT, Bilodeau L, Van der Schaaf RJ, Henriques JP, Vis MM, Baan J Jr, Van der Wal AC, Piek JJ, Tijssen JG, Krucoff MW, De Winter RJ. Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study. JACC Cardiovasc Interv. 2009 Oct;2(10):934-43. doi: 10.1016/j.jcin.2009.07.013.
Results Reference
background
PubMed Identifier
19463340
Citation
Ikari Y, Sakurada M, Kozuma K, Kawano S, Katsuki T, Kimura K, Suzuki T, Yamashita T, Takizawa A, Misumi K, Hashimoto H, Isshiki T; VAMPIRE Investigators. Upfront thrombus aspiration in primary coronary intervention for patients with ST-segment elevation acute myocardial infarction: report of the VAMPIRE (VAcuuM asPIration thrombus REmoval) trial. JACC Cardiovasc Interv. 2008 Aug;1(4):424-31. doi: 10.1016/j.jcin.2008.06.004.
Results Reference
background
PubMed Identifier
19463309
Citation
Vlaar PJ, Svilaas T, Vogelzang M, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan E, Suurmeijer AJ, Zijlstra F. A comparison of 2 thrombus aspiration devices with histopathological analysis of retrieved material in patients presenting with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008 Jun;1(3):258-64. doi: 10.1016/j.jcin.2008.03.014.
Results Reference
background
PubMed Identifier
19161878
Citation
Sardella G, Mancone M, Bucciarelli-Ducci C, Agati L, Scardala R, Carbone I, Francone M, Di Roma A, Benedetti G, Conti G, Fedele F. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009 Jan 27;53(4):309-15. doi: 10.1016/j.jacc.2008.10.017.
Results Reference
background
PubMed Identifier
17985382
Citation
Sardella G, Mancone M, Nguyen BL, De Luca L, Di Roma A, Colantonio R, Petrolini A, Conti G, Fedele F. The effect of thrombectomy on myocardial blush in primary angioplasty: the Randomized Evaluation of Thrombus Aspiration by two thrombectomy devices in acute Myocardial Infarction (RETAMI) trial. Catheter Cardiovasc Interv. 2008 Jan 1;71(1):84-91. doi: 10.1002/ccd.21312.
Results Reference
background
PubMed Identifier
17045887
Citation
Silva-Orrego P, Colombo P, Bigi R, Gregori D, Delgado A, Salvade P, Oreglia J, Orrico P, de Biase A, Piccalo G, Bossi I, Klugmann S. Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol. 2006 Oct 17;48(8):1552-9. doi: 10.1016/j.jacc.2006.03.068. Epub 2006 Sep 26.
Results Reference
background
PubMed Identifier
16504620
Citation
Svilaas T, van der Horst IC, Zijlstra F. Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)--study design. Am Heart J. 2006 Mar;151(3):597.e1-597.e7. doi: 10.1016/j.ahj.2005.11.010.
Results Reference
background
PubMed Identifier
16022970
Citation
Burzotta F, Trani C, Romagnoli E, Mazzari MA, Rebuzzi AG, De Vita M, Garramone B, Giannico F, Niccoli G, Biondi-Zoccai GG, Schiavoni G, Mongiardo R, Crea F. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol. 2005 Jul 19;46(2):371-6. doi: 10.1016/j.jacc.2005.04.057.
Results Reference
background
PubMed Identifier
18775918
Citation
De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J. 2008 Dec;29(24):3002-10. doi: 10.1093/eurheartj/ehn389. Epub 2008 Sep 5.
Results Reference
background
PubMed Identifier
19110787
Citation
Chevalier B, Gilard M, Lang I, Commeau P, Roosen J, Hanssen M, Lefevre T, Carrie D, Bartorelli A, Montalescot G, Parikh K. Systematic primary aspiration in acute myocardial percutaneous intervention: a multicentre randomised controlled trial of the export aspiration catheter. EuroIntervention. 2008 Aug;4(2):222-8. doi: 10.4244/eijv4i2a40.
Results Reference
background
PubMed Identifier
18539223
Citation
Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008 Jun 7;371(9628):1915-20. doi: 10.1016/S0140-6736(08)60833-8.
Results Reference
background
PubMed Identifier
17765119
Citation
Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007 Sep 4;50(10):933-9. doi: 10.1016/j.jacc.2007.04.082. Epub 2007 Aug 20.
Results Reference
background
PubMed Identifier
19463469
Citation
Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, Regar E. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. JACC Cardiovasc Interv. 2009 May;2(5):445-52. doi: 10.1016/j.jcin.2009.01.012.
Results Reference
background
PubMed Identifier
19755289
Citation
Hara H, Nakamura M, Komatsu H, Ikeda N, Shinji H, Makino K, Itaya H, Yamamoto M, Itou N, Tsunoda T, Sugi K. Comparison of the in vitro performance of 6 and 7 French aspiration catheters. EuroIntervention. 2007 Feb;2(4):487-92.
Results Reference
background
PubMed Identifier
16159983
Citation
Grayson AD, Moore RK, Jackson M, Rathore S, Sastry S, Gray TP, Schofield I, Chauhan A, Ordoubadi FF, Prendergast B, Stables RH; North West Quality Improvement Programme in Cardiac Interventions. Multivariate prediction of major adverse cardiac events after 9914 percutaneous coronary interventions in the north west of England. Heart. 2006 May;92(5):658-63. doi: 10.1136/hrt.2005.066415. Epub 2005 Sep 13.
Results Reference
background
PubMed Identifier
15708704
Citation
Guedes A, Keller PF, L'Allier PL, Lesperance J, Gregoire J, Tardif JC. Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J Am Coll Cardiol. 2005 Feb 15;45(4):559-64. doi: 10.1016/j.jacc.2004.10.063.
Results Reference
background
PubMed Identifier
11405500
Citation
Johansson P, Lunden M, Ekstrom L, Grip L, Wennerblom B. Intensive use of intravascular ultrasound during coronary angioplasty. A six-month campaign. Scand Cardiovasc J. 2001 Mar;35(2):75-9. doi: 10.1080/140174301750164655.
Results Reference
background
PubMed Identifier
20142206
Citation
Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention. 2010 Feb;5(7):871-4. doi: 10.4244/eijv5i7a146. No abstract available.
Results Reference
background
PubMed Identifier
23979567
Citation
Muramatsu T, Garcia-Garcia HM, Onuma Y, Zhang YJ, Bourantas CV, Diletti R, Iqbal J, Radu MD, Ozaki Y, Serruys PW; TROFI investigators. Intimal flaps detected by optical frequency domain imaging in the proximal segments of native coronary arteries: an innocent bystander? Insights from the TROFI Trial. Circ J. 2013;77(9):2327-33. doi: 10.1253/circj.cj-13-0357. Epub 2013 Jun 15.
Results Reference
derived
PubMed Identifier
23778184
Citation
Muramatsu T, Garcia-Garcia HM, Onuma Y, Zhang YJ, Bourantas CV, Diletti R, Iqbal J, Radu MD, Ozaki Y, Serruys PW; on behalf of the TROFI investigators. Intimal Flaps Detected by Optical Frequency Domain Imaging in the Proximal Segments of Native Coronary Arteries. Circ J. 2013 Jun 15. Online ahead of print.
Results Reference
derived
PubMed Identifier
22971949
Citation
Muramatsu T, Garcia-Garcia HM, Lee IS, Bruining N, Onuma Y, Serruys PW. Quantitative optical frequency domain imaging assessment of in-stent structures in patients with ST-segment elevation myocardial infarction: impact of imaging sampling rate. Circ J. 2012;76(12):2822-31. doi: 10.1253/circj.cj-12-0536. Epub 2012 Aug 29.
Results Reference
derived
Learn more about this trial
Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients
We'll reach out to this number within 24 hrs